Lymphoma was the first cancer to benefit from chemotherapy over a half century ago. Continuous progress has led to dramatic improvement in the outcome of patients with lymphoma. There has been a clear acceleration in the understanding of the biology of lymphoma, which has led to the development of a number of novel biological agents often called targeted therapies. Such therapies will likely replace chemotherapy in several situations moving forward.
The Lymphoma Division has been at the forefront in the development of many of these novel therapies, particularly in mantle cell lymphoma (all three novel agents approved), diffuse large cell lymphoma, follicular lymphoma, T-cell lymphomas and Hodgkin lymphoma.
Stem cell transplantation, as well as other immunotherapy approaches, particularly the use of checkpoint inhibitors (to unleash the immune system), or genetically modified T-cells (CAR-T cells) will definitely change the future management of lymphoma.